ABI test

The ankle-brachial index (ABI) is one of the few non-imaging tools that can detect significant peripheral artery disease without a scanner or contrast dye. A blood pressure cuff, a Doppler probe, and about ten minutes are all it takes. Beyond diagnosing blocked leg arteries, a low ABI turns out to be a powerful signal of atherosclerosis throughout the body.

What the test measures

Arteries narrowed by plaque resist blood flow, which drops pressure downstream. The ABI captures that drop by comparing systolic blood pressure at the ankle to systolic pressure at the arm. Divide the highest ankle reading by the highest arm reading, and you get the index.

A result between 0.9 and 1.4 is normal. Readings from 0.80-0.89 suggest early concern and warrant closer attention to risk factors. The range 0.6-0.89 raises the possibility of meaningful plaque buildup and generally calls for a physician's input. Below 0.6, significant arterial disease is likely and confirmation testing is appropriate [1].

Why it matters beyond the legs

A low ABI doesn't mean blocked leg arteries. Narrowed peripheral vessels are a marker of systemic atherosclerosis, so a low ankle pressure often flags disease elsewhere in the body at the same time.

The prognostic data are striking. A large individual-patient-data meta-analysis pooling 48,294 participants found that an ABI of 0.90 or below independently predicts both cardiovascular and all-cause mortality, roughly doubling 10-year mortality within every Framingham risk category and adding predictive value on top of the Framingham score itself [2]. Put differently, even among people already classified as high-risk by standard tools, a low ABI identifies a meaningfully higher-risk subgroup.

How well does it perform?

For detecting arterial blockage of 50% or greater, Verhoeven's analysis suggests the ABI has a specificity of roughly 98% and a sensitivity of roughly 90% [1]. Those numbers are encouraging, but they come with an important boundary: performance drops substantially when plaque is early or hasn't yet caused major narrowing. The ABI is designed to catch large-vessel, flow-limiting disease, not subclinical buildup. Self-administered testing may also be less accurate than clinical administration [1].

Who should be cautious about it

Several situations limit the test's reliability or safety. People with diabetes often have medial artery calcification, which artificially stiffens the ankle vessels and inflates the pressure reading, making the result unreliable. The test should be avoided in anyone with deep vein thrombosis or severe leg pain at rest. For accurate results, the person being tested should lie still for at least five minutes beforehand and avoid caffeine or stimulants beforehand [1].

The ABI also cannot substitute for imaging. A normal result is reassuring at the level of large vessels, but it does not rule out early or moderate plaque that hasn't yet caused a 50% blockage. Anyone with a borderline ABI result should have it confirmed by a physician before drawing conclusions or changing management [1].

Where it fits in a screening picture

Verhoeven's analysis positions the ABI as a practical first-pass screen for people with cardiovascular risk factors who haven't had vascular imaging. A normal ABI alongside favorable risk markers provides reasonable reassurance. A reading below 0.8, especially in combination with other risk signals, is generally a prompt to pursue further evaluation such as coronary CT angiography or carotid intima-media thickness testing [1].

Where the evidence is contested

The performance figures cited here (98% specificity, 90% sensitivity) come from Verhoeven's analyst synthesis [1], not directly from a single primary trial, so they should be treated as reasonable working estimates rather than settled benchmarks. Primary literature confirms the ABI's prognostic weight at the population level [2], but the precise sensitivity and specificity values in everyday clinical or self-testing settings are less firmly established. The gap between clinical-grade and consumer-grade Doppler equipment also remains incompletely characterized, meaning real-world self-test accuracy could differ meaningfully from the figures above.

References

1. raw/physionic/physionic-insulin-cause-atherosclerosis.txt
2. ABI Collaboration/Fowkes 2008, JAMA — low ABI → mortality (n=48,294) · PubMed 18612117